Clalit: Pfizer vaccine cuts symptomatic infections 94%
Research analyzing data from 1.2 million Israelis has corroborated the high efficacy in Pfizer s clinical trials.
Israel s Clalit Health Services Research Institute has published its first research paper on the efficacy of the Covid-19 vaccinations and their influence on preventing infection and morbidity in all age groups.
Clalit, Israel s largest health maintenance organization (HMO) analyzed data from 1.2 million members - 600,000 members who received the Pfizer vaccination and 600,000 members with a similar profile who were not vaccinated. The research found that there was a 94% fall in symptomatic infections among those who were vaccinated and a 92% fall in the rate of those who were seriously ill with Covid-19 among the 600,000 who were vaccinated, compared with the 600,000 who did not receive any vaccination. The efficacy was seen in all age groups, including over 70s, who were only represented in a limited group in Pfi